Intellia Therapeutics Inc (NAS:NTLA)
$ 15.21 0.48 (3.26%) Market Cap: 1.55 Bil Enterprise Value: 992.63 Mil PE Ratio: 0 PB Ratio: 1.61 GF Score: 60/100

Intellia Therapeutics Inc at Barclays Global Healthcare Conference Transcript

Mar 15, 2022 / 01:00PM GMT
Release Date Price: $58.27 (-0.90%)
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Okay. Great. My name is Gena Wang. I'm speaking of biotech analyst at the Barclays. Thank you for coming to our first in-person Global Healthcare Conference post pandemic. It is really nice to see everyone in person. I wanted to thank everyone, investors, companies, especially (inaudible) team who made this event possible.

With that, it's my great pleasure to introduce our next presenting company, Intellia. With us today, we have John Leonard, President and Chief Executive Officer.

John, do you want to give a very brief introduction before we dive into the questions?

John M. Leonard
Intellia Therapeutics, Inc. - President, CEO & Director

Sure. Sure. Thank you. I can -- real quickly I can kind of lay out what Intellia is. We call ourselves a full spectrum (inaudible) company, which means we have really 3 legs to the stool, a very, very active in vivo effort where we emphasize systemically administered CRISPR/Cas9. I'm sure we'll be talking about that.

We also

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot